211 related articles for article (PubMed ID: 38104128)
1. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
Respir Res; 2023 Dec; 24(1):317. PubMed ID: 38104128
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
Res Sq; 2023 Sep; ():. PubMed ID: 37841851
[TBL] [Abstract][Full Text] [Related]
3. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
4. A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung.
Sosinski LM; H CM; Neugebauer KA; Ghuneim LJ; Guzior DV; Castillo-Bahena A; Mielke J; Thomas R; McClelland M; Conrad D; Quinn RA
J Cyst Fibros; 2022 Nov; 21(6):996-1005. PubMed ID: 34824018
[TBL] [Abstract][Full Text] [Related]
5. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
Schaupp L; Addante A; Völler M; Fentker K; Kuppe A; Bardua M; Duerr J; Piehler L; Röhmel J; Thee S; Kirchner M; Ziehm M; Lauster D; Haag R; Gradzielski M; Stahl M; Mertins P; Boutin S; Graeber SY; Mall MA
Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37414422
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy.
Hilliam Y; Armbruster CR; Rapsinski GJ; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Cooper VS; Lee SE; Bomberger JM
Microbiol Spectr; 2024 Jun; ():e0078724. PubMed ID: 38916354
[TBL] [Abstract][Full Text] [Related]
8. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.
Fila L; Grandcourtova A; Bilkova A; Drevinek P
Front Pharmacol; 2023; 14():1178009. PubMed ID: 37332357
[No Abstract] [Full Text] [Related]
9. Persistence and evolution of
Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
[TBL] [Abstract][Full Text] [Related]
10. Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.
Wiesel V; Aviram M; Mei-Zahav M; Dotan M; Prais D; Cohen-Cymberknoh M; Gur M; Bar-Yoseph R; Livnat G; Goldbart A; Hazan G; Hazan I; Golan-Tripto I
J Cyst Fibros; 2024 Jan; 23(1):41-49. PubMed ID: 37173154
[TBL] [Abstract][Full Text] [Related]
11. Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.
Gushue C; Eisner M; Bai S; Johnson T; Holtzlander M; McCoy K; Sheikh S
Pediatr Pulmonol; 2023 Aug; 58(8):2308-2316. PubMed ID: 37222417
[TBL] [Abstract][Full Text] [Related]
12. Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.
McNally P; Lester K; Stone G; Elnazir B; Williamson M; Cox D; Linnane B; Kirwan L; Rea D; O'Regan P; Semple T; Saunders C; Tiddens HAWM; McKone E; Davies JC;
Am J Respir Crit Care Med; 2023 Nov; 208(9):917-929. PubMed ID: 37703083
[No Abstract] [Full Text] [Related]
13. Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis.
Casey M; Gabillard-Lefort C; McElvaney OF; McElvaney OJ; Carroll T; Heeney RC; Gunaratnam C; Reeves EP; Murphy MP; McElvaney NG
Thorax; 2023 Aug; 78(8):835-839. PubMed ID: 37208188
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
Nichols DP; Morgan SJ; Skalland M; Vo AT; Van Dalfsen JM; Singh SB; Ni W; Hoffman LR; McGeer K; Heltshe SL; Clancy JP; Rowe SM; Jorth P; Singh PK;
J Clin Invest; 2023 May; 133(10):. PubMed ID: 36976651
[TBL] [Abstract][Full Text] [Related]
15. Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic Fibrosis.
Sheikh S; Ho ML; Eisner M; Gushue C; Paul G; Holtzlander M; Johnson T; McCoy KS; Lind M
JAMA Otolaryngol Head Neck Surg; 2023 Dec; 149(12):1075-1082. PubMed ID: 37676668
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI.
Gill ER; Bartlett LE; Milinic T; Burdis N; Pilewski JM; Dunitz JM; Kapnadak SG; Goss CH; Ramos KJ
J Cyst Fibros; 2024 Jan; 23(1):161-164. PubMed ID: 38008684
[TBL] [Abstract][Full Text] [Related]
17. Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.
Milo F; Ciciriello F; Alghisi F; Tabarini P
J Cyst Fibros; 2023 May; 22(3):414-419. PubMed ID: 36549989
[TBL] [Abstract][Full Text] [Related]
18. Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.
Cavinato L; Luly FR; Pastore V; Chiappetta D; Sangiorgi G; Ferrara E; Baiocchi P; Mandarello G; Cimino G; Del Porto P; Ascenzioni F
Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 36455959
[TBL] [Abstract][Full Text] [Related]
19. Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature.
Tupayachi Ortiz MG; Baumlin N; Yoshida M; Salathe M
Heliyon; 2024 Mar; 10(5):e26955. PubMed ID: 38463894
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria.
Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0110422. PubMed ID: 36286508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
